Arsenic trioxide-mediated antiplatelet activity

pivotal role of the phospholipase Cγ2-protein kinase C-p38 MAPK cascade

Kuan H. Lin, Yi F. Chang, Chiao Y. Fan, Thanasekaran Jayakumar, Jie J. Lee, Duen S. Chou, George Hsiao, Joen Rong Sheu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Arsenic trioxide produces high rates of complete clinical remission in patients with relapsed/refractory acute promyelocytic leukemia. Platelet activation is relevant in a variety of acute thrombotic events and coronary heart diseases. Few studies have examined the effects of arsenic trioxide on platelets, and the mechanisms underlying the signaling pathways remain obscure. The aim of this study was to examine systematically the detailed mechanisms of arsenic trioxide in preventing platelet activation. Arsenic trioxide (5 μmol/L) exhibited more potent activity at inhibiting collagen (1 μg/mL)-induced platelet aggregation than other agonists. Arsenic trioxide (15 and 25 μmol/L) inhibited collagen-induced platelet activation accompanied by [Ca+2]i mobilization, thromboxane A2 (TxA2) formation, phospholipase C (PLC)γ2 phosphorylation, and protein kinase C (PKC) activation. Arsenic trioxide (15 and 25 μmol/L) did not significantly affect cyclic nucleotide-induced vasodilator-stimulated phosphoprotein phosphorylation. Moreover, arsenic trioxide markedly inhibited p38 mitogen-activated protein kinase (MAPK) but not JNK1/2 or ERK2 phosphorylation in washed platelets. Arsenic trioxide also markedly reduced hydroxyl radical (OH·) formation in the erythrocyte sedimentation rate (ESR) study. The most important findings of this study suggest that the inhibitory effect of arsenic trioxide possibly involves inhibition of the PLCγ2-PKC-p38 MAPK cascade, thereby leading to inhibition of [Ca+2]i or free radical formation, and finally the inhibition of platelet aggregation.

Original languageEnglish
Pages (from-to)97-108
Number of pages12
JournalTranslational Research
Volume155
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Phospholipases
p38 Mitogen-Activated Protein Kinases
Protein Kinase C
Platelets
Phosphorylation
Platelet Activation
Chemical activation
Platelet Aggregation
Collagen
Blood Platelets
Agglomeration
arsenic trioxide
Acute Promyelocytic Leukemia
Thromboxane A2
Cyclic Nucleotides
Blood Sedimentation
Type C Phospholipases
Sedimentation
Hydroxyl Radical
Refractory materials

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, medical
  • Public Health, Environmental and Occupational Health

Cite this

Arsenic trioxide-mediated antiplatelet activity : pivotal role of the phospholipase Cγ2-protein kinase C-p38 MAPK cascade. / Lin, Kuan H.; Chang, Yi F.; Fan, Chiao Y.; Jayakumar, Thanasekaran; Lee, Jie J.; Chou, Duen S.; Hsiao, George; Sheu, Joen Rong.

In: Translational Research, Vol. 155, No. 2, 02.2010, p. 97-108.

Research output: Contribution to journalArticle

Lin, Kuan H. ; Chang, Yi F. ; Fan, Chiao Y. ; Jayakumar, Thanasekaran ; Lee, Jie J. ; Chou, Duen S. ; Hsiao, George ; Sheu, Joen Rong. / Arsenic trioxide-mediated antiplatelet activity : pivotal role of the phospholipase Cγ2-protein kinase C-p38 MAPK cascade. In: Translational Research. 2010 ; Vol. 155, No. 2. pp. 97-108.
@article{5036a3b4281f43afa1611e168948fa15,
title = "Arsenic trioxide-mediated antiplatelet activity: pivotal role of the phospholipase Cγ2-protein kinase C-p38 MAPK cascade",
abstract = "Arsenic trioxide produces high rates of complete clinical remission in patients with relapsed/refractory acute promyelocytic leukemia. Platelet activation is relevant in a variety of acute thrombotic events and coronary heart diseases. Few studies have examined the effects of arsenic trioxide on platelets, and the mechanisms underlying the signaling pathways remain obscure. The aim of this study was to examine systematically the detailed mechanisms of arsenic trioxide in preventing platelet activation. Arsenic trioxide (5 μmol/L) exhibited more potent activity at inhibiting collagen (1 μg/mL)-induced platelet aggregation than other agonists. Arsenic trioxide (15 and 25 μmol/L) inhibited collagen-induced platelet activation accompanied by [Ca+2]i mobilization, thromboxane A2 (TxA2) formation, phospholipase C (PLC)γ2 phosphorylation, and protein kinase C (PKC) activation. Arsenic trioxide (15 and 25 μmol/L) did not significantly affect cyclic nucleotide-induced vasodilator-stimulated phosphoprotein phosphorylation. Moreover, arsenic trioxide markedly inhibited p38 mitogen-activated protein kinase (MAPK) but not JNK1/2 or ERK2 phosphorylation in washed platelets. Arsenic trioxide also markedly reduced hydroxyl radical (OH·) formation in the erythrocyte sedimentation rate (ESR) study. The most important findings of this study suggest that the inhibitory effect of arsenic trioxide possibly involves inhibition of the PLCγ2-PKC-p38 MAPK cascade, thereby leading to inhibition of [Ca+2]i or free radical formation, and finally the inhibition of platelet aggregation.",
author = "Lin, {Kuan H.} and Chang, {Yi F.} and Fan, {Chiao Y.} and Thanasekaran Jayakumar and Lee, {Jie J.} and Chou, {Duen S.} and George Hsiao and Sheu, {Joen Rong}",
year = "2010",
month = "2",
doi = "10.1016/j.trsl.2009.08.005",
language = "English",
volume = "155",
pages = "97--108",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Arsenic trioxide-mediated antiplatelet activity

T2 - pivotal role of the phospholipase Cγ2-protein kinase C-p38 MAPK cascade

AU - Lin, Kuan H.

AU - Chang, Yi F.

AU - Fan, Chiao Y.

AU - Jayakumar, Thanasekaran

AU - Lee, Jie J.

AU - Chou, Duen S.

AU - Hsiao, George

AU - Sheu, Joen Rong

PY - 2010/2

Y1 - 2010/2

N2 - Arsenic trioxide produces high rates of complete clinical remission in patients with relapsed/refractory acute promyelocytic leukemia. Platelet activation is relevant in a variety of acute thrombotic events and coronary heart diseases. Few studies have examined the effects of arsenic trioxide on platelets, and the mechanisms underlying the signaling pathways remain obscure. The aim of this study was to examine systematically the detailed mechanisms of arsenic trioxide in preventing platelet activation. Arsenic trioxide (5 μmol/L) exhibited more potent activity at inhibiting collagen (1 μg/mL)-induced platelet aggregation than other agonists. Arsenic trioxide (15 and 25 μmol/L) inhibited collagen-induced platelet activation accompanied by [Ca+2]i mobilization, thromboxane A2 (TxA2) formation, phospholipase C (PLC)γ2 phosphorylation, and protein kinase C (PKC) activation. Arsenic trioxide (15 and 25 μmol/L) did not significantly affect cyclic nucleotide-induced vasodilator-stimulated phosphoprotein phosphorylation. Moreover, arsenic trioxide markedly inhibited p38 mitogen-activated protein kinase (MAPK) but not JNK1/2 or ERK2 phosphorylation in washed platelets. Arsenic trioxide also markedly reduced hydroxyl radical (OH·) formation in the erythrocyte sedimentation rate (ESR) study. The most important findings of this study suggest that the inhibitory effect of arsenic trioxide possibly involves inhibition of the PLCγ2-PKC-p38 MAPK cascade, thereby leading to inhibition of [Ca+2]i or free radical formation, and finally the inhibition of platelet aggregation.

AB - Arsenic trioxide produces high rates of complete clinical remission in patients with relapsed/refractory acute promyelocytic leukemia. Platelet activation is relevant in a variety of acute thrombotic events and coronary heart diseases. Few studies have examined the effects of arsenic trioxide on platelets, and the mechanisms underlying the signaling pathways remain obscure. The aim of this study was to examine systematically the detailed mechanisms of arsenic trioxide in preventing platelet activation. Arsenic trioxide (5 μmol/L) exhibited more potent activity at inhibiting collagen (1 μg/mL)-induced platelet aggregation than other agonists. Arsenic trioxide (15 and 25 μmol/L) inhibited collagen-induced platelet activation accompanied by [Ca+2]i mobilization, thromboxane A2 (TxA2) formation, phospholipase C (PLC)γ2 phosphorylation, and protein kinase C (PKC) activation. Arsenic trioxide (15 and 25 μmol/L) did not significantly affect cyclic nucleotide-induced vasodilator-stimulated phosphoprotein phosphorylation. Moreover, arsenic trioxide markedly inhibited p38 mitogen-activated protein kinase (MAPK) but not JNK1/2 or ERK2 phosphorylation in washed platelets. Arsenic trioxide also markedly reduced hydroxyl radical (OH·) formation in the erythrocyte sedimentation rate (ESR) study. The most important findings of this study suggest that the inhibitory effect of arsenic trioxide possibly involves inhibition of the PLCγ2-PKC-p38 MAPK cascade, thereby leading to inhibition of [Ca+2]i or free radical formation, and finally the inhibition of platelet aggregation.

UR - http://www.scopus.com/inward/record.url?scp=74049137970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049137970&partnerID=8YFLogxK

U2 - 10.1016/j.trsl.2009.08.005

DO - 10.1016/j.trsl.2009.08.005

M3 - Article

VL - 155

SP - 97

EP - 108

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 2

ER -